INSMED INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.15 USD | -2.62% |
|
-11.85% | -22.49% |
Presenter SpeechLee Hung (Analysts)Good morning. Welcome to the Morgan Stanley Global Healthca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
24.8
USD
Average target price
43.87
USD
Spread / Average Target
+76.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.49% | 3.68B | |
| -3.19% | 102B | |
| +1.81% | 96.07B | |
| -1.80% | 21.66B | |
| -17.66% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -27.94% | 13.79B | |
| -0.46% | 13.33B | |
| +20.24% | 10.94B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Transcript : Insmed Incorporated Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 09
